Uniphore Accelerates Expansion Across Europe
10.6.2025 10:02:00 CEST | Business Wire | Press Release
Uniphore, the Business AI Company, today announced a significant expansion across Europe, accelerating its commitment to the region through new customer adoption, partner momentum, product launches, and organizational investment.
The announcement coincides with the release of the Uniphore Business AI Cloud, announced during the AI Leadership Summit held yesterday in London—an exclusive gathering of media, industry leaders, and Uniphore customers exploring the future of agentic AI in Europe. Attendees included executives from ResultsCX, Konecta, KPMG, and Rowan Curran, Principal Analyst at Forrester, who shared perspectives on how enterprises are scaling AI from isolated pilots to business-critical systems that drive measurable outcomes across customer experience, marketing, operations and more.
A Platform Built for Europe's AI Mandate
As enterprise adoption of AI accelerates across Europe, CIOs and Line of Business Leaders face growing pressure to deliver solutions that align with the EU’s AI Act. Uniphore’s Business AI Cloud delivers on these requirements through a sovereign, composable, and secure platform that allows enterprises to activate AI across voice, video, text, structured and unstructured data — without compromising privacy or control.
With generative AI projected to grow at 55 percent annually in Europe and AI spending expected to exceed $133 billion in the region by 2028, European CIOs are under pressure to move beyond experimentation and deliver business-ready AI that is secure, compliant and operational at scale. Uniphore’s Business AI Cloud is built to meet this demand, supporting the CIO mandate to operationalize AI across workflows while meeting strict data governance, privacy and ethical standards defined in the EU AI Act and other regulatory frameworks.
Fall 2025: Uniphore Marketing AI CDP Launches in EMEA
Uniphore will formally launch its Marketing AI CDP and Marketing Agents, part of the Business AI Suite, in the European market this fall. Built for enterprise marketers navigating complex privacy landscapes and fragmented customer data, the solution helps teams activate insights and deploy agentic marketing workflows — without requiring data movement or custom engineering.
Among Uniphore’s newest customers in the region is Hearst UK, a leading media organization embracing AI to drive marketing automation and personalized engagement.
“We’ve been really pleased with the flexibility and composability of the Uniphore CDP,” said Krishan Gandhi, Senior Director of Data Engineering & Analytics at Hearst UK. “As we continue to evolve our customer data strategy, we’re excited to see how Uniphore’s Marketing Agents and complete AI platform will help us better engage audiences, streamline workflows, and drive more impactful marketing outcomes.”
The Uniphore Business AI Suite includes Marketing AI, a CDP with pre-built agents purpose-built for enterprise marketers, including the Product Knowledge Agent (now generally available), which answers user questions in real time using indexed product documentation; the Platform Search Agent, launching in Summer 2025, which enables semantic search across audiences, attributes, and platform components; and the Audience Segmentation Agent, also arriving this summer, which allows marketers to build audience cohorts from plain-English prompts using both rule- and outcome-based logic. Together, these agents help enterprises accelerate first-party data activation while meeting GDPR compliance requirements out of the box.
Momentum with Konecta Drives Scaled Transformation
Uniphore also continues to deepen its relationship with global BPO leader Konecta, following the strategic partnership announced in late 2023. The companies are jointly scaling AI-led contact center transformation across Europe — automating quality monitoring, enabling real-time agent guidance and delivering measurable outcomes for telecom and financial services leaders.
“With Uniphore, we’re building an agentic AI factory, designed to rapidly create, deploy and orchestrate AI agents across our customer environments,” said Oscar Vergé, chief AI deployment officer at Konecta. “The platform’s agent builder, orchestration engine and support for both prebuilt and custom agents allow us to agentify critical workflows for each client, from customer service to back-office automation. This isn’t just AI adoption — it’s real transformation at enterprise scale.”
Konecta leaders joined Uniphore onstage at the AI Leadership Summit in London to discuss deployment momentum and share learnings on production-grade enterprise AI.
Growing the Team and Leadership Across EMEA
Uniphore has significantly grown its presence in the region, expanding its team across sales, engineering, and customer success. The company now operates from a dedicated London office as well as an office in Valencia, Spain and is actively engaged in deployments across key markets throughout EMEA.
To support this growth, Jeremy Keefe has joined as Vice President of Sales, EMEA, bringing decades of enterprise software leadership to Uniphore’s regional go-to-market strategy.
About Uniphore
Uniphore is the Business AI company. Our sovereign, composable, and secure AI platform connects enterprise data, fine-tunes AI models and deploys agentic AI across the enterprise. We empower every worker to boost productivity and help businesses grow faster, operate smarter and reduce costs. Trusted by more than 1,500 businesses globally, and recognized on the Deloitte Fast 500, Uniphore delivers on the promise of AI as a transformative force for business.
Learn more about Uniphore’s Business AI Cloud and enterprise AI solutions at www.uniphore.com. For insights, updates and thought leadership, explore our blog or follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250610372448/en/
Contacts
Media Contact:
Tim Harris
Director, Public Relations
tim.harris@uniphore.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom